The invention relates generally to systems and methods for control of electronic devices. More specifically, the present invention relates to systems and methods for the programming and recharging of medical devices, and especially neurostimulating devices, either by the patient receiving treatment from the device or by a caregiver.
Medical devices are commonly used today to treat patients suffering from various ailments, including by way of example, pain, incontinence, movement disorders such as epilepsy, Parkinson's disease, and spasticity. Additional stimulation therapies appear promising to treat a variety of other medical conditions, including physiological, psychological, and emotional conditions. As the number of stimulation therapies increases, so do the demands placed on these medical devices.
Known stimulation devices, such as cardiac pacemakers, tachyarrhythmia control devices, drug delivery devices, and nerve stimulators, provide treatment therapy to various portions of the body. While the present invention may be used with various medical devices, by way of example and illustration, an implantable pulse generator (IPG) device will be discussed to illustrate the advantages of the invention. In the case of providing electrical stimulation to a patient, an IPG is implanted within the body. The IPG is coupled to one or more electrodes to deliver electrical stimulation to select portions of the patient's body. Neuromuscular stimulation (the electrical excitation of nerves and/or muscle to directly elicit the contraction of muscles), neuromodulation stimulation (the electrical excitation of nerves, often afferent nerves, to indirectly affect the stability or performance of a physiological system) and brain stimulation (the stimulation of cerebral or other central nervous system tissue) can provide functional and/or therapeutic outcomes.
There exist both external and implantable devices for providing beneficial results in diverse therapeutic and functional restorations indications. The operation of these devices typically includes the use of an electrode placed either on the external surface of the skin, a vaginal or anal electrode, or a surgically implanted electrode. Implantable medical devices may be programmable and/or rechargeable, and the devices may log data, which are representative of the operating characteristics over a length of time.
Implantable devices have provided an improvement in the portability of neurological stimulation devices, but there remains the need for continued improvement in the control of such devices either by the patient into whom a device is implanted or by a caregiver. Medical devices are often controlled using microprocessors with resident operating system software. This operating system software may be further broken down into subgroups including system software and application software. The system software controls the operation of the medical device while the application software interacts with the system software to instruct the system software on what actions to take to control the medical device based upon the actual application of the medical device.
As the diverse therapeutic and functional uses of stimulators increase and become more complex, system software having a versatile interface is needed to play an increasingly important role. This interface allows the system software to remain generally consistent based upon the particular medical device, and allows the application software to vary greatly depending upon the particular application. As long as the application software is written so it can interact with the interface, and in turn the system software, the particular medical device can be used in a wide variety of applications with only changes to application specific software. This allows a platform device to be manufactured in large, more cost effective quantities, with application specific customization occurring at a later time.
While handheld programmers are generally known in the art, the programmers are generally controlled only by a treating physician or clinician. Therefore, to modify device settings, an office visit is normally required. Such office visits are especially inefficient where the required adjustment of the medical device is such that the patient or caregiver could accomplish the adjustment with minimal training. Therefore, there exist many gaps in handheld controller devices and methods for the controlling and recharging of medical devices, especially those of the implanted type, either by the patient receiving treatment from the device or by a caregiver.
Furthermore, although it is generally known to use rechargeable power supplies or batteries in implanted medical devices, methods heretofore employed to recharge the implanted devices most often required the patient to remain relatively motionless or in a relaxed position. Since the recharging process for the devices can be lengthy, the limitations in patient movement could hinder the patient's lifestyle, especially if recharging was required during the patient's waking hours. For example, a patient using a prior art method of recharge may be prevented from running simple errands because of the virtual or physical tether to prior art recharging apparatus.
Therefore, the field of medical treatment by implantable medical devices would benefit from a portable apparatus that provides a patient or caregiver the ability to recharge and alter the parameters of an implanted medical device, while at the same time allowing the patient substantially unobstructed mobility.
The present invention comprises a portable apparatus and associated method that provides a patient or caregiver the ability to recharge and alter the parameters of an implanted medical device, while at the same time allowing the patient substantially unobstructed mobility.
Although the disclosure hereof is detailed and exact to enable those skilled in the art to practice the invention, the physical embodiments herein disclosed merely exemplify the invention which may be embodied in other specific structures. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.
Turning now to the Figures,
Disposed on or in the shell 110 are two interfaces; a user input interface 120 and a user output, or feedback, interface 130. The user input interface 120 desirably comprises a plurality of buttons; a power button 122, a mode select pad 124, and a parameter adjustment pad 126. The power button 122 is desirably a push button to power the controller 100 on and off. The mode select pad 124 desirably provides two buttons; a mode up button 124a and a mode down button 124b. The adjustment pad 126 also desirably provides two buttons; an increase button 126a and a decrease button 126b. Furthermore, a select button (not shown) may be included as a part of the user input interface 120, similar to the other buttons. The select button could provide a means of affirmative indication by the user that a setting of the device 100 is acceptable. Desirably, all buttons of the user input interface 120 interface with at least one electronic component contained in the controller 100. The buttons are desirably injection molded silicone rubber.
In addition to the user input interface 120, the controller 100 comprises a user output interface 130. The depicted controller 100 is shown with a liquid crystal display (LCD) screen 131 as the user output interface 130. The function of the user output interface 130 is to provide some visual feedback such as a status or operating mode of the controller 100, a status of a medical device, or a preview of programming parameters to be transferred to the medical device. By utilizing the LCD screen 131, specific diagrammatic figures and parameter values may be displayed. Additional user output display components may include other visual indicators such as simple light-emitting diodes (LEDs), or aural indicators such as piezo buzzers or variable audio tones.
Referring also to
The power supply 152 may be a rechargeable battery 153 and associated charging and indication circuitry 155. The rechargeable battery 153 may be recharged when connected to a power source, such as when the controller 100 is connected by a power adaptor 300 to a wall outlet, or is docked on a docking station (not shown). Addressing safety concerns, the controller 100 desirably may not be used to recharge an IPG 18 while the controller 100, itself, is being recharged through the power adaptor 300. The charging and indication circuitry 155 provides to the microcontroller 154 periodic updates of the status of the battery 153 and charging thereof. The battery 153 is desirably secured in the shell so that it cannot be removed easily, so as to discourage accidental disposal by users.
The programmable microcontroller 154 provides the general intelligence of the controller 100, and desirably includes a predetermined amount of memory to hold desirable software; however, the memory may also be supplied as a separate component. The microcontroller 154 generally controls the operation of the user output interface 130, the accessory controller 156 and the wireless telemetry module 158, all depending upon the mode of operation as selected by the user input interface 120 or some other source.
The accessory controller 156 is desirably a slave to the microcontroller 154 and provides the requisite electronic control of an accessory, such as a charging coil 200. The accessory controller 156 is activated by the microcontroller 154 when the associated accessory is detected as being coupled to the controller 100 through the receptacle 140. A single accessory controller 156 may supply the requisite control of a plurality of accessories, or, alternatively, a plurality of accessory controllers 156 may be supplied.
The telemetry module 158 may incorporate a suitable wireless telemetry transceiver chip set that can operate in the Medical Implant Communications Service (MICS) band (402 MHz to 405 MHz) or other very high frequency (VHF) or ultra high frequency (UHF) low power, unlicensed bands. A wireless telemetry link established between the controller 100 and an implanted medical device is especially useful in motor control applications where a user issues a command to an IPG to produce muscle contractions to achieve a functional goal (e.g., to stimulate ankle flexion to aid in the gait of an individual after a stroke). The wireless telemetry is desirably non-inductive radio frequency telemetry. Therefore, communications between the controller 100 and the IPG 18 desirably does not require a coil, or other component, taped or placed on the skin over the IPG 18, thereby enhancing user maneuverability and allowing communications desirably up to a distance of six feet between the controller 100 and the IPG 18. A suitable transceiver chip that may be used for half duplex wireless communications is the AMIS-52100, available from AMI Semiconductor, Pocatello, Id. This transceiver chip is designed specifically for applications using the MICS band and the MICS European counter-part, the Ultra Low Power-Active Medical Implant (ULP-AMI) band.
The electrical connectors 157 on the PCA 150 may provide operative electrical interconnectivity between the PCA 150 and various electrical components, such as the LCD 131, the receptacle 140, other PCAs, or even a standardized test setup, such as a Joint Test Action Group (JTAG) interface.
User interface components 159 convert user input to electrical signals to be used by the controller 100 and further convert electrical signals into indicators that are to be sensed by a user. As user interface components 160 to the user input interface 130, it is desirable to provide a plurality of split electrical contacts 162 to indicate when a user has communicated through the user input interface 120. The contacts 162 are electrically coupled to the microcontroller 154 to indicate such user activity. An electrically conductive surface is provided on a bottom side of the plurality of buttons on the user input interface 120, so as to connect both sides of the split contacts 162 when a button is depressed. Furthermore, the user interface components 160 further comprise the parts of the user output interface 130, such as the LCD 131.
The power adaptor 300 provides the ability to recharge the controller battery 153. It comprises a power plug 302, converter 303, and a power cord 304. The power plug 302 is a conventional power plug adapted to cooperate with any standard wall outlet socket. The converter 303 receives alternating current power from the standard wall outlet socket, through the plug 302, and presents the appropriate voltage required by the battery charging circuitry 155 in the controller 100. The appropriate voltage is presented through the power cord 304, which includes a power connector 306, mateable with the controller receptacle 140. Alternating current power cords are generally known in the art, and many variations are available.
A second controller embodiment 400 is shown in
The user output interface 430 is provided desirably in the form of a plurality of light emitting diodes (LEDs) 431-435. The LEDs have different display functionality depending upon the incident operating state of the electronic components within the controller 400. Similar to the first embodiment 100, the second embodiment 400 contains various electronic components (not shown). The second embodiment 400 desirably includes a non-rechargeable battery as its power supply and does not include an accessory controller. Therefore, the primary function of a reduced size controller, such as the second embodiment 400, is the adjustment of stimulation parameters and monitoring of IPG status rather than recharging the IPG battery.
It is to be appreciated that the controller 100 may take on any convenient shape, such as a ring on a finger, a watch on a wrist, or an attachment to a belt, for example. It may also be desirable to separate the functions of the controller 100 into a charger and a patient controller.
Turning to
The rechargeable battery of the IPG 18 may be recharged by the application of a transcutaneous low frequency RF magnetic field applied by a charging coil 200 mounted on a patient's skin or clothing and placed over or near the IPG 18. The transcutaneous RF magnetic field may have a frequency range of about 30 Khz to about 300 Khz. To begin charging, the charging coil 200 is placed proximate the IPG 18 and connected by the coil cable 204 to the controller 100, and electrically coupled to the accessory controller 156 through the controller receptacle 140. The coil 200 may be held in place manually, but it is desirable that the coil 200 be removably fastened to the skin by way of the adhesive backing strip (208 in
The controller 100 and the IPG 18, as shown in
During the battery recharge period, the IPG 18 may transmit status information, such as an indication of the battery charge status and an indication of the magnitude of power recovered by the receive coil 200, back to the controller 100.
Based on the magnitude of the power recovered, the smart charge allows the controller 100 to automatically adjust up or down the magnitude of the magnetic field and/or to instruct the user to reposition the charging coil 200 based on the status information to allow optimal recharging of the battery of the IPG 18 while minimizing unnecessary power consumption by the controller 100 and power dissipation in the IPG 18 (through circuit losses and/or through absorption by the implantable pulse generator case 20 and other components). The magnitude of the RF magnetic field 100 may be automatically adjusted up to about 300 percent or more of the initial magnitude of the RF magnetic field and adjusted down until the controller 100 stops generating the RF magnetic field. Adjustment of the RF magnetic field 100 may also result from sensing a desirable temperature on the skin side of the charging coil 200. That is, the magnitude may be increased or decreased if a sensed temperature is low enough or too high, respectively. Temperature sensing may be achieved by any general way known in the art, such as a thermistor or thermocouple.
The instructions to the user to reposition the charging coil 200 may be a visual instruction, such as a bar graph on the controller 100, or a display on the controller 100 showing relative positions of the charging coil 200 and the IPG 18, or an audio instruction, such as a varying tone to indicate relative position, or a combination of instructions.
In addition to a rechargeable battery, the IPG 18 may incorporate wireless telemetry for a variety of functions, such as receipt and transmission of stimulus parameters and settings, receiving requests for and transmitting battery and operating status, allowing user control of the implantable pulse generator 18, and for assisting in the control of the RF magnetic field generated by the controller 100. To enable reliable wireless communications, each IPG may have a unique signature that limits communication to only certain dedicated controllers. This signature could be a serial number that is stored in the IPG in non-volatile electronic memory or by other means. While an interface device or controller used by a clinician or physician may be configured for use with many patients and many IPGs by configuring the clinical programmer with various desired serial numbers, such broad functionality is not generally desirable for patients or caregivers.
The controller 100 is desirably the master of all wireless communications between it and an IPG 18. Therefore, to begin a wireless communication, the controller 100 generates and sends a wireless telemetry communication to an IPG 18, the communication including the IPG's unique serial number and data elements that indicate the communication is a command from an external controller 100. Only the IPG 18 having the unique serial number responds to the communication from the controller 100. The communication response includes elements that indicate the communication is a response to a command from an external controller 100, and that the communication is not a command from a different external controller.
Communications protocols include appropriate received message integrity testing and message acknowledgment handshaking to assure the necessary accuracy and completeness of every message. Some operations (such as reprogramming or changing stimulus parameters) require rigorous message accuracy testing and acknowledgement. Other operations, such as a single user command value in a string of many consecutive values, might require less rigorous checking and no acknowledgement or a more loosely coupled acknowledgement. Integrity testing may be accomplished through the use of parity bits in the communication messages or even the use of a cyclic redundancy check (CRC) algorithm. Implementation of parity and CRC algorithms are generally known in the communications art.
The timing with which an IPG enables its transceiver to search for RF telemetry from an external controller may be precisely controlled (using a time base established by a quartz crystal) at a relatively low rate, e.g., the IPG may look for commands from the external controller for about two milliseconds at a rate of two (2) Hz or less. This equates to a monitoring interval of about ½ second or less. It is to be appreciated that an IPG's enabled transceiver rate and the monitoring rate may vary faster or slower depending on the application. This precise timing allows the external controller to synchronize its next command with the time that the IPG will be listening for commands. This, in turn, allows commands issued within a short time (seconds to minutes) of the last command to be captured and acted upon without having to ‘broadcast’ an idle or pause signal for a full received monitoring interval before actually issuing the command in order to know that the IPG will have enabled its receiver and be ready to receive the command. Similarly, the communications sequence may be configured to have the external controller issue commands in synchronization with the IPG listening for commands. Similarly, the command set implemented may be selected to minimize the number of messages necessary and the length of each message consistent with the appropriate level of error detection and message integrity monitoring. It is to be appreciated that the monitoring rate and level of message integrity monitoring may vary faster or slower depending on the application, and may vary over time within a given application.
The wireless telemetry communications may also be used in conjunction with the IPG battery charging function. It is especially useful in cases where two implant charger controllers 100 could be erroneously swapped, or where two or more IPGs 18 may be within wireless telemetry range of each other. For example, when two users live in the same home, a first IPG 18 could communicate with its controller 100 even when the charging coil 200 is erroneously positioned over another IPG 18. The controller 100 is configured to communicate and charge a specifically identified IPG, or a target IPG, which is identified by the unique signature or serial number. If the target IPG is wirelessly communicating with a controller 100 that is erroneously positioned, the target IPG communicates with the controller 100 to increase the magnitude of the RF magnetic field. This communication may continue until the magnitude of the RF magnetic field is at its maximum.
In order to stop a controller 100 from attempting to charge the incorrect IPG 18, the controller 100 may periodically decrease the magnitude of the RF magnetic field and then wirelessly communicate with the target IPG 18 to determine whether the target IPG 18 sensed the decrease in the magnitude. If the charging coil 200 is erroneously positioned over an IPG other than the target IPG 18, the target IPG 18 will not sense the decrease and will indicate to the controller 100 that it did not sense the decrease. The controller 100 will then restore the original RF magnetic field strength and retry the reduced RF magnetic field test. Multiple failures of the test may cause the controller 100 to suspend charging and notify the user 1 of the error. Similarly, should the IPG 18 not recover usable power from the RF magnetic field after a few minutes, the controller 100 will suspend charging and notify the user 1 of the error.
Operation of the system can perhaps best be described with a working example explaining different operating modes of the controller 100 incorporating an LCD screen 131. Generally, the controller 100 operates so as to provide an interface between an IPG and a patient in which the device is implanted, or a caregiver thereof. The controller 100 provides the ability for the patient to recharge the IPG, query the IPG regarding its present settings, to adjust the IPG settings, and to recharge the controller 100. As shown in the flowchart in
OFF: The controller 100 may enter the OFF mode from any other mode by a mere passage of time, or the user may affirmatively enter the OFF mode from any operating mode.
While the controller 100 is in the OFF mode, controller power consumption is minimal and the user output interface 130 is desirably deactivated. Optionally, however, a simple “heartbeat” or other nominal indication may be shown on the output interface 130 to represent some state of the controller.
From the OFF mode, the controller 100 may enter the PROD_ID mode or the IMP_STAT mode. To enter the PROD_ID mode, there are desirably two methods of removing the controller 100 from the OFF mode. First, a user could depress the power button 122. While depression of other buttons on the controller 100 could possibly turn the device 100 on, to minimize accidental activation, it is desirable that only one button, the power button 122, activate the device 100. Second, a user could supply power to the controller 100 through a power adaptor 300. Therefore, if the controller 100 entered the OFF mode without error, when the controller 100 wakes from the OFF mode, it desirably enters the PROD_ID mode. If, on the other hand, the controller 100 was in the IMP_STAT mode and had a fatal system error occur prior to entering the OFF mode, the controller 100, upon leaving the OFF mode, desirably enters the IMP_STAT mode with an error indicator displayed, as shown in one embodiment in
PROD_ID: The controller 100 may enter the PROD_ID, or product identification, mode from the OFF mode.
Upon entering the PROD_ID mode, a temporary indicator such as an informational screen, or “splash screen,” may be displayed, including information such as device information, manufacturer, software revision, date, time, etc. This screen or plurality of indicators remains active for a predetermined amount of time before entering the next mode.
From the PROD_ID mode, the controller 100 may enter the following modes: IMP_STAT, LOC_COIL, or CTRL_CHG. The mode following the PROD_ID mode depends on whether an accessory is connected, and, if so, which accessory is connected. If no accessory is connected, the mode switches from PROD_ID to IMP_STAT. If the power adaptor 300 is connected through the controller receptacle 140, the next mode is CTRL_CHG. Finally, if the charge coil 200 is connected through the controller receptacle 140, the next mode is LOC_COIL.
IMP_STAT: The controller 100 may enter the IMP_STAT, or implant status, mode from the following modes: OFF, PROD_ID, REV_ADJ, LOC_COIL, IMP_CHG, or CTRL_CHG. If the controller 100 entered the OFF state during an error condition, powering on the controller 100 preferably places it in the IMP_STAT mode with an indication of the error state. Assuming no accessory is connected as the controller 100 is exiting the PROD_ID mode, the controller 100 enters the IMP_STAT mode. From the REV_ADJ mode, IMP_STAT is entered by a mere passage of one of the following: a predetermined amount of time after REV_ADJ mode was entered; a predetermined amount of time after any parameter modifications are made; or, a predetermined amount of time after a predetermined combination of the mode buttons 124a,124b are depressed. From the LOC_COIL mode or from the IMP_CHG mode, the controller 100 may enter the IMP_STAT mode where a charge coil 200 is disconnected and fails to be reconnected within a predetermined amount of time. From the CTRL_CHG mode, the controller 100 enters the IMP_STAT mode if the power adaptor 300 is disconnected from the controller 100. The predetermined amounts of time may be anything greater than zero seconds, but is desirably between 3 and 30 seconds.
The IMP_STAT mode may be a desirable base operating mode on top of which other modes may run. Upon entering the IMP_STAT mode, information is displayed to the user. If the cause of entering this mode is a disconnected charge coil 200, it is desirable to display an indication of the charge coil 200 disconnect that has occurred. Furthermore, through the user output interface 130, it is desirable to convey three pieces of information. One item is the battery charge status of the controller 100. The other two items depend on whether successful wireless communications can be established with the IPG 18. If communications are not established, a message to that effect is desirably displayed. If communications can be established, the battery charge status of the IPG 18 is displayed, along with a present parameter setting, such as a stimulus intensity level. Rather than the three listed pieces of information, or in addition to that information, other status indicators or user commands could also be displayed through the user output interface 130.
From the IMP_STAT mode, the controller may enter the following modes: OFF, REV_ADJ, LOC_COIL, and CTRL_CHG. The user may do nothing, or may depress the power button 122, for a predetermined period of time, and the controller 100 desirably proceeds to the OFF mode. The user may depress a button on the mode select pad 124 to enter the REV_ADJ mode. To enter the LOC_COIL mode, the user may connect a charge coil 200 to the controller receptacle 140. Finally, the user may connect a power adaptor 300 to the controller receptacle 140 and to an active wall socket to enter the CTRL_CHG mode.
REV_ADJ: The controller 100 may enter the REV_ADJ, or review and adjust settings, mode from the following modes: IMP_STAT or IMP_CHG. If the user is in either of these modes and depresses the mode select button 124, the controller 100 will switch into the REV_ADJ mode.
In this mode, the user has the option to adjust various settings both of the controller 100 and of the IPG 18. While the REV_ADJ mode is active, the mode select button 124 allows the user to scroll between parameters. For example, the user may wish to alter the volume of an audio indicator from the controller 100. The user simply navigates to the volume parameter using the mode select button 124 and then changes the volume setting by using the parameter adjustment button 126. Other parameters may be adjusted, such as IPG stimulation intensity and IPG stimulation activation. The stimulation intensity is generally only a vague, abstract number to the patient. That is, the patient's physician will dictate the various stimulation profiles available to the patient through the use of the controller 100 in combination with the IPG 18. The patient will only see, desirably, a numerical indicator of which profile is activated and may possibly reference a correlative list of what those numerical indicators actually mean with regards to the technical settings of the IPG 18, such as pulse width, amplitude and frequency of the stimulation. Therefore, as seen in
From the REV_ADJ mode, the controller 100 may enter all of the modes from which the mode may have been entered: IMP_STAT or IMP_CHG. The mode to which the controller 100 proceeds depends on which mode it was in before the REV_ADJ mode was entered. It may return to the mode from which it came by the mere passage of a predetermined period of inactivity, by the depression of the power button 122.
LOC_COIL: The controller 100 may enter the LOC_COIL, or locate charging coil, mode from the following modes: PROD_ID, IMP_STAT or IMP_CHG. From the PROD_ID mode, if a charging coil 200 is coupled to the controller 100, it enters the LOC_COIL mode automatically. From the IMP_STAT mode, rather than plug in the power adaptor 300 to the receptacle, the user could connect the charging coil 200 to the controller 100 causing it to enter the LOC_COIL mode. From the IMP_CHG mode, if the inductive coupling between the charge coil 200 and the IPG 18 becomes ineffective for purposes of charging, the controller 100 may be forced into the LOC_COIL mode. An implementation of the LOC_COIL mode can be seen in
Once in the LOC_COIL mode, a visual indication is displayed and the controller 100 emits a locating tone. The screen 131 displays a graphical indication of the quality of the charging coil 200 placement proximate the IPG 18, and further includes an indicator, graphical or textual, that appears when the quality of the charging coil 200 placement is adequate to allow normal charging of the IPG battery. Desirably, depression of either the mode button 124 or the parameter adjustment button 126 has no effect on the controller 100 during the time it is locating the proper placement of the coil 200. While maneuvering the coil 200 to locate the IPG 18, and throughout charging, the user is informed as to the quality and status of the charging progress, desirably visually and aurally. The user should especially be informed if the coil cable 204 becomes unplugged from the controller 100. Once the locating tone and/or display indicate that the coil 200 is in proper charging position, the user can begin charging by pressing the power button 122 to enter the IMP_CHG mode.
Two periods of inactivity will cause the controller 100 to at least imply repositioning of the coil 200 and/or the controller 100 to enable proper charging. First, if no wireless telemetry is successful for a predetermined period, the controller 100 warns the user of the lack of wireless communications with the IPG 18. Also, during coil location, periodic updates of coil location quality are calculated to provide adequate feedback to the user. However, if no wireless telemetry between the controller 100 and IPG 18 has been successful between a predetermined number of charge coil updates, the controller 100 will not indicate to the user that placement of the coil 200 is adequate for normal charging.
From the LOC_COIL mode, the controller 100 may enter the following modes: OFF, IMP_STAT and IMP_CHG. Inactivity on the part of the user for a predetermined time, three minutes for example, desirably causes the controller 100 to enter the OFF mode. The IMP_STAT mode is entered when a charge coil 200 is disconnected and fails to be reconnected within a predetermined amount of time. The IMP_CHG mode is entered when the user is satisfied with the positioning of the charging coil 200 and a triggering event occurs. The triggering event could be the depression of the power button 122 or the achievement of a predetermined charging power.
IMP_CHG: The controller may enter the IMP_CHG, or implant charging, mode from the following modes: LOC_COIL or REV_ADJ. Entry into this mode is caused by the occurrence of a triggering event. The triggering event may be a user-initiated event or an automatic reactive event. The user-initiated triggering event may be the depression of a button. The automatic reactive triggering event may be the mere passage of time, or even a sensed charge coil placement position.
The IMP_CHG mode desirably runs on top of the IMP_STAT mode. Once in the IMP_CHG, an indication is displayed on the LCD 131. While in this mode, the accessory controller 156 is driving the connected charging coil 200. The user output interface 130 indicates to the user the fact that charging is taking place, and may also indicate the status of the IPG battery charge. While in this mode, the user may also alter the settings of the IPG 18.
From the IMP_CHG mode, the controller 100 may enter the following modes of operation: OFF, IMP_STAT, REV_ADJ, LOC_COIL, CHG_DONE, or CTRL_CHG. The user may affirmatively cancel the charging process, in which case the controller 100 desirably enters the OFF mode or IMP_STAT mode. Depression of the mode select button 124 will cause the controller 100 to enter the REV_ADJ mode and provide indication to the user. The IMP_CHG mode completes when the IPG is fully charged or when the charge in the controller battery 153 is insufficient to continue adequate charging. When the IMP_CHG is not interrupted and allowed to proceed to completion, the controller 100 enters the CHG_DONE mode.
CHG_DONE: The controller 100 may enter the CHG_DONE, or charge done, mode from the IMP_CHG mode. The CHG_DONE mode is entered upon the occurrence of either a completely charged IPG 18 battery or upon the depletion of the controller battery 153 to a point where further implant charging would be ineffective. Desirably, although continued IPG charging may not be allowed, the depletion point would allow enough controller battery 153 charge to allow basic operation of the controller 100.
Status is communicated to the user through the user output interface 130. Desirably, no wireless communications occur between the controller 100 and the IPG 18 in this mode.
From the CHG_DONE mode, the controller 100 may proceed to the following modes: OFF or IMP_STAT. To place the controller 100 in the OFF mode from the CHG_DONE mode, the power button 122 is depressed for a predetermined period of time, or the controller could enter the OFF mode after a predetermined period of inactivity. Alternatively, if the charge coil is removed from the controller 100, it enters the IMP_STAT mode.
CTRL_CHG: The controller 100 may enter the CTRL_CHG mode from the following modes: PROD_ID, IMP_STAT or IMP_CHG. Entering from either PROD_ID or IMP_STAT mode occurs if power is supplied to the controller 100 by a connected power adaptor 300. The CTRL_CHG mode is entered from the IMP_CHG mode if the power adaptor 300 is coupled to the controller 100 within a predetermined amount of time from a disconnection of the charge coil 200. In this case, the unplugged coil 200 status may be communication through the user output interface 130 prior to entering the CTRL_CHG mode.
While in the CTRL_CHG mode, an indicator is displayed to the user through the user output interface 130. Where the user output interface 130 is an LCD 131, the indicator may be a separate screen, or simply an indicator displayed in combination with other screens. The indication provided may be that of the present controller battery 153 level and an indication that the battery is charging.
From the CTRL_CHG mode, the controller 100 may enter the following modes: OFF, IMP_STAT, or SN_MOD. The controller 100 enters the OFF mode if the power button 122 is depressed for a predetermined amount of time. The IMP_STAT mode is entered when the power adaptor 300 is disconnected from the controller 100, or when the controller battery 153 has been charged to a predetermined level. Finally, the controller 100 enters the SN_MOD mode when a certain combination of buttons is pressed.
SN_MOD: The controller 100 may enter the SN_MOD, or serial number modification, mode from the CTRL_CHG mode. The SN_MOD mode is entered by depressing a certain combination of buttons on the face of the controller 100 within a predetermined time. This mode is desirably not available to the patient or caregiver and is supplied primarily for maintenance of the device or review of the device settings by a supervising physician.
While in the SN_MOD mode, the physician may modify the serial number of the IPG with which the controller 100 should be communicating. This modification is accomplished by using the user input interface 120 and the user output interface 130.
From the SN_MOD mode, the controller 100 may enter either the OFF mode or the CTRL_CHG mode. To enter the OFF mode, the physician merely depresses the power button 122 for a predetermined period of time. If the power button 122 remains unpressed for a period of time, the controller 100 desirably returns to the CTRL_CHG mode from which it came to enter the SN_MOD mode.
Lastly, turning to a method of operation of the second embodiment 400 of the handheld controller, depicted in a user's hand in
Thus, when the IPG battery power is queried, the LEDs would illuminate from left to right indicating percentage of battery life remaining. Thus, to indicate 80% IPG battery life, the four leftmost LEDs would illuminate. To indicate 40% IPG battery life, the two leftmost LEDs would illuminate. The LEDs would switch off at the earlier of a predetermined time or the turning off of the power switch.
The foregoing is considered as illustrative only of the principles of the invention. Furthermore, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described.
This application is a continuation-in-part of co-pending U.S. patent application Ser. No. 11/516,890, filed 7 Sep. 2006, and entitled “Implantable Pulse Generator Systems and Methods for Providing Functional and/or Therapeutic Stimulation of Muscles and/or Nerves and/or Central Nervous System Tissue,” which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/801,003, filed 17 May 2006, and entitled “Implantable Pulse Generator for Providing Functional and/or Therapeutic Stimulation of Muscle and/or Nerves and/or Central Nervous System Tissue.”
Number | Name | Date | Kind |
---|---|---|---|
3421511 | Schwartz et al. | Jan 1969 | A |
3654933 | Hagfors | Apr 1972 | A |
3727616 | Lenzkes | Apr 1973 | A |
3774618 | Avery | Nov 1973 | A |
3870051 | Brindley | Mar 1975 | A |
3902501 | Citron et al. | Sep 1975 | A |
3926198 | Kolenik | Dec 1975 | A |
3939841 | Dohring et al. | Feb 1976 | A |
3939843 | Smyth | Feb 1976 | A |
3941136 | Bucalo | Mar 1976 | A |
3943932 | Woo | Mar 1976 | A |
3943938 | Wexler | Mar 1976 | A |
4232679 | Schulman | Nov 1980 | A |
4254775 | Langer | Mar 1981 | A |
4257423 | McDonald | Mar 1981 | A |
4262678 | Stokes | Apr 1981 | A |
4398545 | Wilson | Aug 1983 | A |
4406288 | Horwinski et al. | Sep 1983 | A |
4407303 | Akerstrom | Oct 1983 | A |
4512351 | Pohndorf | Apr 1985 | A |
4519404 | Fleischhacker | May 1985 | A |
4569351 | Tang | Feb 1986 | A |
4573481 | Bullara | Mar 1986 | A |
4585005 | Lue et al. | Apr 1986 | A |
4585013 | Harris | Apr 1986 | A |
4590689 | Rosenberg | May 1986 | A |
4590946 | Loeb | May 1986 | A |
4592360 | Lesnick | Jun 1986 | A |
4602624 | Naples et al. | Jul 1986 | A |
4607639 | Tanagho et al. | Aug 1986 | A |
4628942 | Sweeney et al. | Dec 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4658515 | Oatman | Apr 1987 | A |
4703755 | Tanagho et al. | Nov 1987 | A |
4716888 | Wesner | Jan 1988 | A |
4721118 | Harris | Jan 1988 | A |
4739764 | Lue et al. | Apr 1988 | A |
4741341 | Marach | May 1988 | A |
4750499 | Hoffer | Jun 1988 | A |
4771779 | Tanagho et al. | Sep 1988 | A |
4793353 | Borkan | Dec 1988 | A |
4835372 | Gombrich et al. | May 1989 | A |
4920979 | Bullara | May 1990 | A |
4926875 | Rabinovitz et al. | May 1990 | A |
4934368 | Lynch | Jun 1990 | A |
4940065 | Tanagho et al. | Jul 1990 | A |
4989617 | Memberg et al. | Feb 1991 | A |
5095905 | Klepinski | Mar 1992 | A |
5113869 | Nappholz et al. | May 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
D337820 | Hooper et al. | Jul 1993 | S |
5235980 | Varrichio et al. | Aug 1993 | A |
5257634 | Kroll | Nov 1993 | A |
5265608 | Lee et al. | Nov 1993 | A |
5282845 | Bush et al. | Feb 1994 | A |
5289821 | Swartz | Mar 1994 | A |
5300107 | Stokes et al. | Apr 1994 | A |
5324322 | Grill, Jr. et al. | Jun 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335664 | Nagashima | Aug 1994 | A |
5344439 | Otten | Sep 1994 | A |
5369257 | Gibbon | Nov 1994 | A |
5370671 | Maurer et al. | Dec 1994 | A |
5397338 | Grey et al. | Mar 1995 | A |
5400784 | Durand et al. | Mar 1995 | A |
5411537 | Munshi et al. | May 1995 | A |
5449378 | Schouenborg | Sep 1995 | A |
5454840 | Krakovsky et al. | Oct 1995 | A |
5461256 | Yamada | Oct 1995 | A |
5476500 | Fain et al. | Dec 1995 | A |
5480416 | Garcia et al. | Jan 1996 | A |
5486202 | Bradshaw | Jan 1996 | A |
5487756 | Kallesoe et al. | Jan 1996 | A |
5505201 | Grill, Jr. et al. | Apr 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5562717 | Tippey et al. | Oct 1996 | A |
5588960 | Edwards et al. | Dec 1996 | A |
5607461 | Lathrop | Mar 1997 | A |
5634462 | Tyler et al. | Jun 1997 | A |
5645586 | Meltzer | Jul 1997 | A |
5669161 | Huang | Sep 1997 | A |
5683432 | Goedeke et al. | Nov 1997 | A |
5683447 | Bush et al. | Nov 1997 | A |
5690693 | Wang et al. | Nov 1997 | A |
5702431 | Wang et al. | Dec 1997 | A |
5713939 | Nedungadi et al. | Feb 1998 | A |
5716384 | Snell | Feb 1998 | A |
5722482 | Buckley | Mar 1998 | A |
5722999 | Snell | Mar 1998 | A |
5733313 | Barreras et al. | Mar 1998 | A |
5733322 | Starkebaum | Mar 1998 | A |
5741313 | Davis et al. | Apr 1998 | A |
5741319 | Woloszko et al. | Apr 1998 | A |
5752977 | Grevious et al. | May 1998 | A |
5755767 | Doan et al. | May 1998 | A |
5759199 | Snell | Jun 1998 | A |
5807397 | Barreras | Sep 1998 | A |
5824027 | Hoffer et al. | Oct 1998 | A |
5843141 | Bischoff et al. | Dec 1998 | A |
5857968 | Benja-Athon | Jan 1999 | A |
5861015 | Benja-Athon | Jan 1999 | A |
5861016 | Swing | Jan 1999 | A |
5899933 | Bhadra et al. | May 1999 | A |
5919220 | Stieglitz et al. | Jul 1999 | A |
5922015 | Schaldach | Jul 1999 | A |
5938596 | Woloszko et al. | Aug 1999 | A |
5948006 | Mann | Sep 1999 | A |
5957951 | Cazaux et al. | Sep 1999 | A |
5984854 | Ishikawa et al. | Nov 1999 | A |
6004662 | Buckley | Dec 1999 | A |
6016451 | Sanchez-Rodarte | Jan 2000 | A |
6026328 | Peckham et al. | Feb 2000 | A |
6055456 | Gerber | Apr 2000 | A |
6055457 | Bonner | Apr 2000 | A |
6061596 | Richmond et al. | May 2000 | A |
6091995 | Ingle et al. | Jul 2000 | A |
6125645 | Horn | Oct 2000 | A |
6126611 | Bourgeois et al. | Oct 2000 | A |
6166518 | Echarri et al. | Dec 2000 | A |
6169925 | Villaseca et al. | Jan 2001 | B1 |
6181965 | Loeb et al. | Jan 2001 | B1 |
6181973 | Ceron et al. | Jan 2001 | B1 |
6185452 | Schulman et al. | Feb 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6212431 | Hahn et al. | Apr 2001 | B1 |
6216038 | Hartlaub et al. | Apr 2001 | B1 |
6240316 | Richmond et al. | May 2001 | B1 |
6240317 | Villaseca et al. | May 2001 | B1 |
6249703 | Stanton et al. | Jun 2001 | B1 |
6257906 | Price et al. | Jul 2001 | B1 |
6266557 | Roe et al. | Jul 2001 | B1 |
6275737 | Mann | Aug 2001 | B1 |
6292703 | Meier et al. | Sep 2001 | B1 |
6308101 | Faltys et al. | Oct 2001 | B1 |
6308105 | Duysens et al. | Oct 2001 | B1 |
6319208 | Abita et al. | Nov 2001 | B1 |
6319599 | Buckley | Nov 2001 | B1 |
6321124 | Cigaina | Nov 2001 | B1 |
6338347 | Chung | Jan 2002 | B1 |
6345202 | Richmond et al. | Feb 2002 | B2 |
6360750 | Gerber et al. | Mar 2002 | B1 |
6370433 | Hartlaub et al. | Apr 2002 | B1 |
6381496 | Meadows et al. | Apr 2002 | B1 |
6409675 | Turcott | Jun 2002 | B1 |
6432037 | Eini et al. | Aug 2002 | B1 |
6442432 | Lee | Aug 2002 | B2 |
6442433 | Linberg | Aug 2002 | B1 |
6445955 | Michelson et al. | Sep 2002 | B1 |
6449512 | Boveja | Sep 2002 | B1 |
6450172 | Hartlaub et al. | Sep 2002 | B1 |
6453198 | Torgerson et al. | Sep 2002 | B1 |
6456866 | Tyler et al. | Sep 2002 | B1 |
6464672 | Buckley | Oct 2002 | B1 |
6482154 | Haubrich et al. | Nov 2002 | B1 |
6493587 | Eckmiller et al. | Dec 2002 | B1 |
6493881 | Picotte | Dec 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6505077 | Kast et al. | Jan 2003 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6535766 | Thompson et al. | Mar 2003 | B1 |
6539253 | Thompson et al. | Mar 2003 | B2 |
6542776 | Gordon et al. | Apr 2003 | B1 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6567703 | Thompson et al. | May 2003 | B1 |
6574510 | Von Arx et al. | Jun 2003 | B2 |
6580947 | Thompson | Jun 2003 | B1 |
6591137 | Fischell et al. | Jul 2003 | B1 |
6597954 | Fischell et al. | Jul 2003 | B1 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6607500 | DaSilva et al. | Aug 2003 | B2 |
6613953 | Altura | Sep 2003 | B1 |
6622037 | Kasano | Sep 2003 | B2 |
6622048 | Mann et al. | Sep 2003 | B1 |
6641533 | Causey et al. | Nov 2003 | B2 |
6643552 | Edell et al. | Nov 2003 | B2 |
6650943 | Whitehurst et al. | Nov 2003 | B1 |
6652449 | Gross et al. | Nov 2003 | B1 |
6658300 | Govari et al. | Dec 2003 | B2 |
6660265 | Chen | Dec 2003 | B1 |
6672895 | Scheiner | Jan 2004 | B2 |
6684109 | Osypka | Jan 2004 | B1 |
6687543 | Isaac | Feb 2004 | B1 |
6701188 | Stroebel et al. | Mar 2004 | B2 |
6721602 | Engmark et al. | Apr 2004 | B2 |
6735474 | Loeb et al. | May 2004 | B1 |
6735475 | Whitehurst et al. | May 2004 | B1 |
6754538 | Linberg | Jun 2004 | B2 |
6775715 | Spitaels et al. | Aug 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
6836684 | Rijkhoff et al. | Dec 2004 | B1 |
6836685 | Fitz | Dec 2004 | B1 |
6845271 | Fang et al. | Jan 2005 | B2 |
6850803 | Jimenez et al. | Feb 2005 | B1 |
6855410 | Buckley | Feb 2005 | B2 |
6856506 | Doherty | Feb 2005 | B2 |
6859364 | Yuasa et al. | Feb 2005 | B2 |
6862480 | Cohen et al. | Mar 2005 | B2 |
6868288 | Thompson | Mar 2005 | B2 |
6891353 | Tsukamoto | May 2005 | B2 |
6893395 | Kraus et al. | May 2005 | B1 |
6895280 | Meadows et al. | May 2005 | B2 |
6904324 | Bishay | Jun 2005 | B2 |
6907293 | Grill et al. | Jun 2005 | B2 |
6907295 | Gross et al. | Jun 2005 | B2 |
6920539 | Qawami et al. | Jul 2005 | B2 |
6925330 | Kleine | Aug 2005 | B2 |
6928320 | King | Aug 2005 | B2 |
6931284 | Engmark et al. | Aug 2005 | B2 |
6937894 | Isaac et al. | Aug 2005 | B1 |
6963780 | Ruben et al. | Nov 2005 | B2 |
6974411 | Belson | Dec 2005 | B2 |
6990376 | Tanagho | Jan 2006 | B2 |
6999819 | Swoyer et al. | Feb 2006 | B2 |
7031768 | Anderson et al. | Apr 2006 | B2 |
7047078 | Boggs, II et al. | May 2006 | B2 |
7078359 | Stepanian et al. | Jul 2006 | B2 |
7101607 | Mollendorf | Sep 2006 | B2 |
7103923 | Picotte | Sep 2006 | B2 |
7118801 | Ristic-Lehmann | Oct 2006 | B2 |
7136695 | Pless | Nov 2006 | B2 |
7167756 | Torgerson et al. | Jan 2007 | B1 |
7177690 | Woods et al. | Feb 2007 | B2 |
7177698 | Klosterman et al. | Feb 2007 | B2 |
7187968 | Wolf | Mar 2007 | B2 |
7187983 | Dahlberg et al. | Mar 2007 | B2 |
7191012 | Boveja | Mar 2007 | B2 |
7198603 | Penner et al. | Apr 2007 | B2 |
7225032 | Schmeling et al. | May 2007 | B2 |
7239918 | Strother et al. | Jul 2007 | B2 |
7254448 | Almendinger et al. | Aug 2007 | B2 |
7269457 | Shafer et al. | Sep 2007 | B2 |
7280872 | Mosesov et al. | Oct 2007 | B1 |
7317947 | Wahlstrand | Jan 2008 | B2 |
7328068 | Spinelli et al. | Feb 2008 | B2 |
7342793 | Ristic-Lehmann | Mar 2008 | B2 |
7343202 | Mrva et al. | Mar 2008 | B2 |
7369897 | Boveja | May 2008 | B2 |
7376467 | Thrope | May 2008 | B2 |
7475245 | Healy et al. | Jan 2009 | B1 |
7499758 | Cates | Mar 2009 | B2 |
7565198 | Bennett | Jul 2009 | B2 |
8195304 | Strother | Jun 2012 | B2 |
20010022719 | Armitage et al. | Sep 2001 | A1 |
20020007198 | Haupert et al. | Jan 2002 | A1 |
20020019652 | Da Silva et al. | Feb 2002 | A1 |
20020026224 | Thompson et al. | Feb 2002 | A1 |
20020055761 | Mann et al. | May 2002 | A1 |
20020055779 | Andrews | May 2002 | A1 |
20020077572 | Fang et al. | Jun 2002 | A1 |
20020109621 | Khair et al. | Aug 2002 | A1 |
20020123672 | Christophersom et al. | Sep 2002 | A1 |
20020161403 | Meadows et al. | Oct 2002 | A1 |
20020164474 | Buckley | Nov 2002 | A1 |
20030018365 | Loeb | Jan 2003 | A1 |
20030065368 | VanDerHoeven | Apr 2003 | A1 |
20030074030 | Leyde et al. | Apr 2003 | A1 |
20030078633 | Firlik et al. | Apr 2003 | A1 |
20030088295 | Cox | May 2003 | A1 |
20030100930 | Cohen et al. | May 2003 | A1 |
20030114897 | Von Arx et al. | Jun 2003 | A1 |
20030114898 | Von Arx et al. | Jun 2003 | A1 |
20030114905 | Kuzma | Jun 2003 | A1 |
20030120259 | Mickley | Jun 2003 | A1 |
20030139783 | Kilgore et al. | Jul 2003 | A1 |
20030149459 | Von Arx et al. | Aug 2003 | A1 |
20030220673 | Snell | Nov 2003 | A1 |
20040030360 | Eini et al. | Feb 2004 | A1 |
20040059392 | Parramon et al. | Mar 2004 | A1 |
20040082977 | Engmark et al. | Apr 2004 | A1 |
20040088024 | Firlik et al. | May 2004 | A1 |
20040093093 | Andrews | May 2004 | A1 |
20040098068 | Carbunaru et al. | May 2004 | A1 |
20040147886 | Bonni | Jul 2004 | A1 |
20040150963 | Holmberg | Aug 2004 | A1 |
20040204744 | Penner et al. | Oct 2004 | A1 |
20040209061 | Farnworth | Oct 2004 | A1 |
20050004619 | Wahlstrand et al. | Jan 2005 | A1 |
20050038491 | Haack | Feb 2005 | A1 |
20050055063 | Loeb et al. | Mar 2005 | A1 |
20050080463 | Stahmann | Apr 2005 | A1 |
20050107841 | Meadows et al. | May 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050149146 | Boveja et al. | Jul 2005 | A1 |
20050175799 | Farnworth | Aug 2005 | A1 |
20050192526 | Biggs et al. | Sep 2005 | A1 |
20050277844 | Strother et al. | Dec 2005 | A1 |
20050277999 | Strother et al. | Dec 2005 | A1 |
20050278000 | Strother et al. | Dec 2005 | A1 |
20060004421 | Bennett et al. | Jan 2006 | A1 |
20060025829 | Armstrong et al. | Feb 2006 | A1 |
20060033720 | Robbins et al. | Feb 2006 | A1 |
20060035054 | Stepanian et al. | Feb 2006 | A1 |
20060085039 | Hastings et al. | Apr 2006 | A1 |
20060100673 | Koinzer | May 2006 | A1 |
20060113955 | Nunally | Jun 2006 | A1 |
20060122660 | Boveja et al. | Jun 2006 | A1 |
20060173507 | Mrva et al. | Aug 2006 | A1 |
20060184208 | Boggs et al. | Aug 2006 | A1 |
20060271112 | Martinson et al. | Nov 2006 | A1 |
20070060967 | Strother et al. | Mar 2007 | A1 |
20070060980 | Strother et al. | Mar 2007 | A1 |
20070100411 | Bonde | May 2007 | A1 |
20070123952 | Strother | May 2007 | A1 |
20070239224 | Bennett et al. | Oct 2007 | A1 |
20080071322 | Mrva et al. | Mar 2008 | A1 |
20080097564 | Lathrop | Apr 2008 | A1 |
20080132969 | Bennett et al. | Jun 2008 | A1 |
Number | Date | Country |
---|---|---|
2121219 | Oct 1995 | CA |
WO0019939 | Apr 2000 | WO |
WO 0183029 | Nov 2001 | WO |
WO03092227 | Apr 2003 | WO |
WO2006055547 | May 2006 | WO |
WO 2006055547 | May 2006 | WO |
WO2009058984 | May 2009 | WO |
Entry |
---|
Mar. 2002 Physician's Manual: Cyberonics Model 201 NeuroCybernetic Prosthesis (NCP) Programming Wand, pp. 1-18. |
Aug. 2002 Physician's Manual: Cyberonics Models 100 and 101 NeuroCybernetic Prosthesis System, NCP Pulse Generator, pp. 1-92. |
2005 Advanced Neuromodulation Systems, Inc., ANS Medical—Determining chronic pain causes and treatments; website: http://www.ans-meeical.com/medicalprofessional/physician/rechargeableipgsystems.cfm. |
2004 Advanced Bionics Corporation Summary of Safety and Effectiveness, pp. 1-18. |
2004 Advanced Bionics Corporation Physician Implant Manual. |
2005 Cyberonics VNS Therapy website: http://www.vnstherapy.com/Epilepsy/hcp/forsurgeons/implantedcomponents.aspx. |
2004 Advanced Bionics Corporation Patient System Handbook. |
Oct. 2001 Advanced Neurostimulation Systems, Inc. ANS Genesis Neurosimulation System Programmer User's Guide. |
Nov. 21, 2001 Advanced Neuromodulation Systems, Inc. (ANS) Summary of Safety and Effectivenss Data, pp. 1-17. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration dated Jul. 18, 2008 for corresponding PCT Application No. PCT/US2008/002540 (10 pgs.). |
U.S. Appl. No. 11/516,890, filed Sep. 7, 2006 by Strothers et al, entitled: Implantable Pulse Generator Systems and Methods for Providing Functional and/or Therapeutic Stimulation of Muscles and/or Nerves and/or central nervous system tissue. |
U.S. Appl. No. 60/486,573, filed Jul. 11, 2003, Loeb et al. |
A Breakthrough in Advanced Materials, Aspen Aerogels, Inc. (1 pg) www.aerogels.com, 2003. |
Bemelmans, Bart L.H., et al., “Neuromodulation by Implant for Treating Lower Urinary Tract Symptoms and Dysfunction,” Eur. Urol. Aug. 1999 36(2): 81-91. |
Bower, W.F., et al., “A Urodynamic Study of Surface Neuromodulation versus Sham in Detrusor Instability and Sensory Urgency”, J. Urology 1998; 160: 2133-2136. |
Brindley, G., et al., “Sacral Anterior Root Stimulators for Bladder Control in Paraplegia”, Paraplegia 1982; 20(6):365-381. |
Caldwell, C. (1971) Multielectrode Electrical Stimulation of Nerve, in Development of Orthotic Systems using Functional Electrical Stimulation and Myoelectric Control, Final Report Project #19-P-58391-F-01, University of Lublinana, Faculty of Electrical Engineering, Lubjiana, Yugoslavia. |
Corbett, Scott S., http://crisp.cit.nih.gov/ Abstract, High-Density Liquid Crystal Polymer Cochlear Electrodes, downloaded Sep. 18, 2006. |
Craggs, M., and McFarlane, J.P., “Neuromodulation of the Lower Urinary Tract,” Experimental Physiology, 84, 149-160 1999. |
Crampon et al., “Nerve Cuff Electrode with Shape Memory Alloy Armature: Design and Fabrication”, Bio-Medical Materials and Engineering 12 (2002) 397-410. |
Craggs, M., et al., “Aberrant reflexes and function of the pelvic organs following spinal cord injury in man”, Autonomic Neuroscience: Basic & Clinical, 126-127 (2006), 355-370. |
Crampon et al., “New Easy to Install Nerve Cuff Electrode Using Shape Memory Alloy Armature”, Artificial Organs, 23(5):392-395, 1999. |
Dalmose, A.L., et al., “Conditional Stimulation of the Dorsal Penile/Clitoral Nerve”, Neurourol Urodyn 2003; 22(2):130-137. |
Edell, David J., PhD, Boston Healthcare Research Device, Feb. 15, 2006. |
Fossberg, E., et al. “Maximal Electrical Stimulation in the Treatment of Unstable Detrusor and Urge Incontinence”, Eur Urol 1990; 18:120-123. |
Grill, et al., “Emerging clinical applications of electrical stimulation: opportunities for restoration of function”, Journal of Rehabilitation Research and Development, vol. 38, No. 6, Nov./Dec. 2001. |
Grill, W. M., Mortimer, J.T., (1996) Quantification of recruitment properties of multiple contact cuff electrodes, IEEE Transactions on Rehabilitation Engineering 4(2):49-62. |
Grill, W.M., (2001) “Selective Activation of the Nervous System for Motor System Neural Prosthesis” in Intelligent Systems and Technologies in Rehabilitation Engineering, H-N.L. Teodorescu, L. C. Jain, Eds., CRC Press, pp. 211-241. |
Gustafson, K., et al. “A Urethral Afferent Mediated Excitatory Bladder Reflex Exists in Humans”, Neurosci Lett 2004: 360(1-2):9-12. |
Gustafson, K., et al., “A Catheter Based Method to Activate Urethral Sensory Nerve Fibers”, J Urol 2003: 170(1):126-129. |
Jezernik, S., “Electrical Stimulation for the Treatment of Bladder Dysfunction: Current Status and Future Possibilities”, Neurol. Res. 2002: 24:413-30. |
Jezernik, S., et al., “Detection and inhibition of hyper-reflexia-like bladder contractions in the cat by sacral nerve root recording and electrical stimulation,” Neurourology and Urodynamics, 20(2), 215-230 (2001). |
Jiang, C., et al., “Prolonged Increase in Micturition Threshold Volume by Anogenital Afferent Stimulation in the Rat”, Br J. Urol. 1998: 82(3):398-403. |
Jiang, C-H., et al., “Prolonged enhancement of the micturition reflex in the cat by repetitive stimulation of bladder afferents,” Journal of Physiology, 517.2 599-605 (1999). |
Juenemann, K., et al., Clinical Significance of Sacral and Pudendal Nerve Anatomy:, J. Urol. 1988; 139(1):74-80. |
Lee, Y.H., et al., “Self-Controlled dorsal penile nerve stimulation to inhibit bladder hyperreflexia in incomplete spinal injury: A case report,” Arch Phys Med Rehabil., 83, 273-7 (2002). |
Loeb et al., “Cuff Electrodes for Chronic Stimulation and Recording of Peripheral Nerve Activity”, Journal of Neuroscience Methods, 64 (1996), 95-103. |
Madersbacher, H., Urinary Urge and Reflex Incontinence:, Urologe A. 1991: 30(4): 215-222 (Abstract only, article in German). |
Mazieres, L., et al., “Bladder Parasympathetic Response to Electrical Stimulation of Urethral Afferents in the Cat”, Neurol Urodynam 1997; 16:471-472. |
Mazieres, L., et al., “The C Fibre Reflex of the Cat Urinary Bladder”, J. Physiol 1998; 513 (Pt 2):531-541. |
McNeal, D.R., (1974) Selective Stimulation, in Annual Reports of Progress, Rehabilitation Engineering Center, Ranchio Los Amigos Hospital, Downey, CA, pp. 24-25. |
McNeal, D.R., Bowman, B.R., (1985) Selective activation of muscles using peripheral nerve electrodes. Med. and Biol. Eng. and Comp., 23:249-253. |
Modern Plastics Worldwide, Notables: 10 Waves of the Future by Modern Plastics Editorial Staff, Sample Molding in Progress: Sep. 1, 2005. |
Nakamura, M., et al., “Bladder Inhibition by Penile Electrical Stimulation”, Br J Urol 1984: 56:413-415. |
Naples, et al., “A Spiral Nerve Cuff Electrode for Peripheral Nerve Stimulation”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 11, Nov. 1988. |
NeuroControl Corp., NeuroControl StiM System brochure. |
NeuroControl Corp., The NeuroControl StiM System, “World's First Miniturized Multi-Channel Programmable Neuromuscular Stimulator” brochure. |
Nissenkorn, Israel, and De Jong, Peter R., 2005 Biocontrol Medical Article: “Lower Urinary Tract,” pp. 1253-1258. |
Oliver, S., et al., “Measuring the Sensations of Urge and Bladder Filling During Cystometry in Urge Incontinence and the Effects of Neuromodulation”, Neurourol Urodyn 2003: 22:7-16. |
Previnaire, J.G., “Short-Term Effect of Pudendal Nerve Electrical Stimulation on Detrusor Hyperreflexia in Spinal Cord Injury Patients: Importance of Current Strength”, Paraplegia 1996: 34:95-99. |
Rijkhoff, N., et al., “Urinary Bladder Control by Electrical Stimulation: Review of Electrical Stimulation Techniques in Spinal Cord Injury”, Neurourol Urodyn 1997; 16(1):39-53. |
Riley, George A., PhD, www.flipchips.com, Advanced Packaging—Water Level Hermetic Cavity Packaging, originally published in Advanced Packaging Magazine, May 2004. |
Riley, George A., PhD, www.flipchips.com, Tutorial 31—Jun. 2003, A survey of Water Level Hermetic Cavity Chip Scale Packages for RF Applications. |
Romero et al., “Neural Morphological Effects of Long-Term Implantation of the Self-Sizing Spiral Cuff Nerve Electrode”, Medical & Biological Engineering & Computing, 2001, vol. 39, pp. 90-100. |
Sahin et al., “Spiral Nerve Cuff Electrode for Recordings of Respiratory Output”, The Spiral Nerve Cuff Electrode, 1997 American Physiological.Society, pp. 317-322. |
Schmidt, R.A., “Applications of Neurostimulation in Urology”, 1988; 7:585-92. |
Spinelli, M., et al., “A New Minimally Invasive Procedure for Pudendal Nerve Stimulation to Treat Neurogenic Bladder: Description of the Method and Preliminary Data”, Neurourol and Urodyn. 2005: 24:305-309. |
Starbuck, D. L., Mortimer, J.T., Sheally, C.N., Reswick, J.B. (1966) An implantable electrodes system for nerve stimulation, Proc 19th Ann. Conf. on Eng. In Med. and Biol. 8:38. |
Starbuck, D.L. (1965) Myo-electric control of paralyzed muscles. IEEE Transactions on Biomedical Engineering 12(3):169-172, Jul.-Oct. |
Sundin, T., et al., “Detrusor inhibition induced from mechanical stimulation of the anal region and from electrical stimulation of pudendal nerve afferents,” Investigative Urology, 5, 374-8 (1974). |
Sweeney, et al., “A Nerve Cuff Technique for Selective Excitation of Peripheral Nerve Trunk Regions”, IEEE Transactions on Biomedical Engineering, vol. 37, No. 7, Jul. 1990. |
Talaat, M., “Afferent Impulses in the Nerves Supplying the Urinary Bladder”, Journal of Physiology 1937: 89-1-13. |
Tanagho, E.A., et al. “Electrical Stimulation in the Clinical Management of the Neurogenic Bladder”, J. Urol. 1988; 140:1331-1339. |
Tyler, et al., “Chronic Response of the Rat Sciatic Nerve to the Flat Interface Nerve Electrode”, Annals of Biomedical Engineering, vol. 31, pp. 633-642, 2003. |
Veraart, C., Grill, W.M., Mortimer, J.T., (1993) Selective control of muscle activation with a multipolar nerve cuff electrode, IEEE Trans. Biomed. Engineering 40:640-653. |
Vodusek, D.B., et al. “Detrusor Inhibition Induced by Stimulation of Pudendal Nerve Afferents”, Neuroul and Urodyn., 1986; 5:381-389. |
Wheeler, et al., “Bladder inhibition by penile nerve stimulation in spinal cord injury patients”, The Journal of Urology, 147(1), 100-3 (1992). |
Wheeler, et al., “Management of Incontinent SCI patients with Penile Stimulation; Preliminary Results,” J. Am. Paraplegia Soc. Apr. 1994: 17(2):55-9. |
www.devicelink.com, MPMN, May 2004, Liquid-Crystal Polymer Meets the Challenges of RF Power Packaging; The plastic air-cavity packages are hermetically sealed using a proprietary process, Susan Wallace. |
www.foster-miller.com, Project Examples, Packaging for Implantable Electronics, Foster-Miller, Inc. Feb. 15, 2006. |
www.machinedesign.texterity.com, Vacuum-Formed Films for Fit and Function, High-Performance Films can Replace Injection-Molded Plastics When Space is at a Premium, David Midgley, Welch Fluorocarbon Inc., Dover, NH Oct. 7, 2004. |
Yang, C., et al., “Peripheral Distribution of the Human Dorsal Nerve of the Penis”, J. Urol 1998; 159(6):1912-6, discussion 1916. |
PCT Search Report dated Feb. 2, 2009 for PCT/US08/081762 (7 pgs.). |
Reply to Written Opinion dated Nov. 13, 2008 for PCT/US07/014396 (13 pgs.). |
Notification of Transmission of IPRP dated Jun. 26, 2009 for PCT/US07/014396 (7 pgs.). |
Notification of Transmittal of the International Search Report and Written Opinion dated Jul. 18, 2008 for PCT/US08/002540 (10 pgs.). |
PCT Written Opinion dated Feb. 2, 2009 for PCT/US08/081762 (10 pgs.). |
Office Action dated Jun. 26, 2009 for U.S. Appl. No. 11/824,931 (11 pgs.). |
Restriction Requirement dated Sep. 9, 2009 for U.S. Appl. No. 11/517,213 (7 pgs.). |
Response dated Oct. 8, 2009 for U.S. Appl. No. 11/517,213 (1 pg.). |
Restriction Requirement dated Jul. 25, 2008 for U.S. Appl. No. 11/712,379 (10 pgs.). |
Response dated Oct. 27, 2008 for U.S. Appl. No. 11/712,379 (1 pg.). |
Office Action dated Dec. 22, 2008 for U.S. Appl. No. 11/712,379 (9 pgs.). |
Responsive Amendment dated Apr. 22, 2009 for U.S. Appl. No. 11/712,379 (11 pgs.). |
Office Action dated Jul. 6, 2009 for U.S. Appl. No. 11/712,379 (12 pgs.). |
Responsive Amendment dated Sep. 8, 2009 for U.S. Appl. No. 11/712,379 (8 pgs.). |
Advisory Action dated Sep. 30, 2009 for U.S. Appl. No. 11/712,379 (3 pgs.). |
Office Action dated Jan. 22, 2010 for U.S. Appl. No. 11/517,213 (16 pgs.). |
Responsive Amendment dated Apr. 22, 2010 for U.S. Appl. No. 11/517,213 (21 pgs.). |
Office Action dated Jun. 25, 2010 for U.S. Appl. No. 11/517,213 (7 pgs.). |
Responsive Amendment dated Aug. 25, 2010 for U.S. Appl. No. 11/517,213 (17 pgs.). |
Office Action dated Dec. 9, 2010 for U.S. Appl. No. 11/517,213, (16 pgs). |
Responsive Amendment dated Mar. 9, 2011 for U.S. Appl. No. 11/517,213, (17 pgs). |
MCP7381/2/3/4 Datasheet, “Advance Single or Dual Cell Lithium-Ion/Lithium-Polymer Charge Management Controllers,” Microchip Technology Inc., 2004 (24 pgs.). |
Office Action dated Apr. 20, 2011 for U.S. Appl. No. 11/517,213, (18 pgs). |
Response dated Jun. 20, 2011 for U.S. Appl. No. 11/517,213, (18 pgs). |
Supplemental European Search Report dated Apr. 21, 2011 for European Application No. 07777090.7 (6 pgs.). |
Office Action dated Jul. 14, 2011 for U.S. Appl. No. 11/974,279, (17 pgs). |
Responsive Amendement dated Oct. 14, 2011 for U.S. Appl. No. 11/794,279, (20 pgs.). |
Final Office Action dated Oct. 13, 2011 for U.S. Appl. No. 12/825,089, (11 pgs.). |
Responsive Amendment dated Dec. 13, 2011 for U.S. Appl. No. 12/825,089, (14 pgs.). |
Respose to Communication dated May 10, 2011 for European Application No. 07777090.7 (2029219) filed Nov. 21, 2011, (37 pgs). |
Examination Report dated Feb. 9, 2012 for European Patent Application No. 07777090.7-2305, 5 pgs.). |
Supplemental Search Report dated Aug. 8, 2012 for European Application No. 08 72 61202, (8 pgs.). |
Response dated Jun. 11, 2012 for European Application No. 07777090.7, (8 pgs.). |
Response to Office Action dated Mar. 30, 2015, from U.S. Appl. No. 11/517,213, filed Jun. 30, 2015, 12 pp. |
Decision on Appeal from U.S. Appl. No. 11/517,213, dated Dec. 12, 2014, 21 pp. |
Office Action from U.S. Appl. No. 12/825,089, dated Dec. 5, 2013, 12 pp. |
Notice of Allowance from U.S. Appl. No. 11/517,213, mailed Nov. 30, 2015, 5 pp. |
Decision on Appeal from U.S. Appl. No. 11/517,170, dated Sep. 15, 2014, 18 pp. |
Notice of Allowance from U.S. Appl. No. 11/517,170, dated Apr. 13, 2015, 9 pp. |
Final Office Action from U.S. Appl. No. 11/517,213, dated Sep. 18, 2015, 6 pp. |
Notice of Allowance from U.S. Appl. No. 11/517,170, mailed Aug. 3, 2015, 9 pp. |
Final Office Action from U.S. Appl. No. 15/063,073, dated Aug. 12, 2016, 8 pp. |
Number | Date | Country | |
---|---|---|---|
20070270921 A1 | Nov 2007 | US |
Number | Date | Country | |
---|---|---|---|
60801003 | May 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11516890 | Sep 2006 | US |
Child | 11712379 | US |